# Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)

> **NCT00133250** · PHASE4 · COMPLETED · sponsor: **Deutsches Herzzentrum Muenchen** · enrollment: 800 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** Abciximab
- **OTHER:** Placebo Heparin Sodium

## Key facts

- **NCT ID:** NCT00133250
- **Lead sponsor:** Deutsches Herzzentrum Muenchen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2008-02
- **Final completion:** 2008-03
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2010-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133250, "Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00133250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*